Global Markets Direct’s, ‘Acute Lung Injury - Pipeline Review, H1 2016’, provides an overview of the Acute Lung Injury pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Acute Lung Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Lung Injury and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
- The report provides a snapshot of the global therapeutic landscape of Acute Lung Injury - The report reviews pipeline therapeutics for Acute Lung Injury by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Acute Lung Injury therapeutics and enlists all their major and minor projects - The report assesses Acute Lung Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Acute Lung Injury
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Acute Lung Injury - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Acute Lung Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Our reports have been used by over 10K customers, including:
Acute Bronchitis Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Acute Bronchitis Global Clinical Trials Review, H2, 2018" provides an overview of Acute Bronchitis clinical trials scenario.This report provides top line data relating to the clinical trials on Acute...
Acute Lung Injury Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Acute Lung Injury Global Clinical Trials Review, H2, 2018" provides an overview of Acute Lung Injury clinical trials scenario.This report provides top line data relating to the clinical trials on...
Acute Pharyngitis Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Acute Pharyngitis Global Clinical Trials Review, H2, 2018" provides an overview of Acute Pharyngitis clinical trials scenario.This report provides top line data relating to the clinical trials on...
Chronic Respiratory Disease Drug Development Pipeline Review, 2018 Summary Asthma is a chronic disease involving the airways in the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include...
136 pages •
By IQ4I Research & Consultancy Pvt. Ltd
• Dec 2018
“Diabetic Foot Ulcer (DFU) Pipeline Analysis” gives comprehensive insights on the various drugs being developed for the treatment of DFU. The report covers all the drugs that are in various phases of development (Discovery, Preclinical and Clinical). The pipeline focuses on novel pharmacologic drugs and regenerative...
Allergic Asthma Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Allergic Asthma Global Clinical Trials Review, H2, 2018" provides an overview of Allergic Asthma clinical trials scenario.This report provides top line data relating to the clinical trials on Allergic...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.